Advances in the research of stealth nanoparticles as antitumor drugs carrier

Chinese Pharmaceutical Journal

Volumn 39, Issue 2, 2004, Pages 89-92

  Fang, Chao ^a   Pei, Yuan Ying ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG CARRIER; FIBRONECTIN; LIPOPROTEIN; MACROGOL; MALEIMIDE; NANOCAPSULE; NANOPARTICLE; POLOXAMER; POLOXAMINE 908; POVIDONE;

ARTICLE; MONONUCLEAR PHAGOCYTE; NEUTROPHIL; PERMEABILITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; RETICULOENDOTHELIAL SYSTEM;

EID: 2442491180     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres [J]. Adv Drug Deliv Rev, 1995,16(2-3):215.
2. Gaur U, Sahoo SK, De TK, et al. Biodistribution of fluoreseinated dextran using novel nanoparticles evading reticuloendothelial system [J]. Int J Pharm, 2000,202(1-2):1.
3. Mitra S, Gaur U, Ghosh PC, et al. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier [J]. J Controlled Release, 2001,74(1-3):317.
4. Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers [J]. Adv Drug Deliv Rev, 1995,16(2-3):195.
5. Gref R, Luck M, Quellec P, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption [J]. Colloids Surf B Biointerfaces, 2000,18(3-4):301.
6. Peracchia MT, Harnisch S, Pinto-Alphandary H, et al. Visualization in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles [J]. Biomaterials, 1999,20(14):1269.
7. Mosqueira VCF, Legrand P, Gulik A, et al. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules [J]. Biomaterials, 2001,22(22):2967.
8. Fontana G, Licciardi M, Mansueto S, et al. Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake [J]. Biomaterials, 2001,22(21):2857.
9. Mosqueira VC, Legrand P, Gref R, et al. Interactions between a macrophage cell line (J774A1) and interface-modified pol (D, L-lactide) nanocapsules bearing poly(ethylene glycol) [J]. J Drug Target, 1999,7(1):65.
10. Li YP, Pei YY, Zhou ZH, et al. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-α carriers: pharmacokinetics and anti-tumor effects [J]. Biol Pharm Bull, 2001,24(6):662.
11. Avgoustakis K, Beletsi A, Panagi Z, et al. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties [J]. J Controlled Release, 2002,79(1-3):123.
12. Utreja S, Khopade AJ, Jain NK. Lipoprotein-mimicking biovectorized systems for methotrexate delivery [J]. Pharm Acta Helv, 1999,73 (6):275.
13. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting [J]. Adv Enzyme Regul, 2001,41:189.
14. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review [J]. J Controlled Release, 2000,65(1-2):271.
15. Shanna D, Chelvi TP, Kaur J, et al. Novel taxol formulation: poly-vinylpyrrolidone nanoparticle-encapsulated taxol for drug delivery in cancer therapy [J]. Oncol Res, 1996,8(7-8):281.
16. Reszka R, Beck P, Fichtner I, et al. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice [J]. J Pharmacol Exp Ther, 1997,280(1):232.
17. Allemann E, Rousseau J, Brasseur N, et al. Photodynamic therapy of tumours with hexadecafluoro zinc phthalocyanine formulated in PEG-coated poly(lactic acid) nanoparticles [J]. Int J Cancer, 1996,66 (6):821.
18. Stella B, Arpicco S, Peracchia MT, et al. Design of folic acid-conjugated nanoparticles for drug targeting [J]. J Pharm Sci, 2000,89 (11):1452.
19. Olivier JC, Huertas R, Lee HJ, et al. Synthesis of pegylated immunonanoparticles [J]. Pharm Res, 2002, 19(8):1137.